Cellyan Biotechnology Co. Class AHKPD
13F holders, Q2 2025 (June 30)6holders +2
3new positions
1sold out
$1.27avg. 13F price*
At the end of Q2 2025, 6 institutions reported holding Cellyan Biotechnology Co. Class A (HKPD) in their 13F filings, up 2 from Q1 2025. 3 opened new positions and 1 sold out. The largest holders were UBS Group AG ($27K), Jane Street Group, LLC ($22K) and Valley National Advisers Inc. ($16K).
- Company
- Cellyan Biotechnology Co. Class A
- Filed as
- HONG KONG PHARMA DIGITAL TEC (Q2 2025)
- CUSIP
- G6365B104
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $30K |
| Exits | 1 | $16K |
All 13F filers, Q1 2025 → Q2 2025: 44,244 shares bought and 22,364 shares sold, net +21,880 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| UBS Group AG | 0.00% | Add +7574.6% | 20,875 | $27K |
| Jane Street Group, LLC | 0.00% | Reduce -17.7% | 17,026 | $22K |
| Valley National Advisers Inc. | 0.00% | New | 13,000 | $16K |
| Clear Street LLC | 0.00% | Reduce -23.5% | 12,019 | $15K |
| Two Sigma Securities, LLC | 0.00% | New | 10,329 | $13K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 312 | $399 |
"% of holder's portfolio" is HKPD's weight in each manager's 13F, not the share of Cellyan Biotechnology Co. Class A the manager owns.